TRPC6遺伝子プロモーターの機能的な単核酸多形態は,イディオパシー性肺動脈高血圧と関連している
Ying Yu1, Steve H Keller, Carmelle V Remillard
1Department of Medicine, University of California, San Diego, La Jolla, CA 92093-0725, USA. Ying.Yu@AlconLabs.com
Circulation
|April 22, 2009
まとめ
TRPC6遺伝子プロモーターの特定の遺伝的変異である-254C->G単核酸多形態 (SNP) は,イディオパシー性肺動脈高血圧 (IPAH) のリスクの増加と関連しています. このSNPは,核因子-kappaB経由でTRPC6発現を高め,IPAH発現に寄与する.
科学分野:
- 心血管遺伝学 心血管遺伝学
- 肺高血圧の病理生理学 肺高血圧の病理生理学
- 分子生物学は分子生物学である.
背景:
- 肺動脈の滑らかな筋肉細胞 (PASMCs) の過剰な増殖は,イディオパシー性肺動脈高血圧 (IPAH) の鍵です.
- PASMCにおける細胞溶液Ca2+濃度の上昇は,収縮と増殖を誘発する.
- TRPC6チャネルのアップレギュレーションは,IPAH患者におけるPASMCの増殖に関与しています.
研究 の 目的:
- IPAHに関連したTRPC6遺伝子プロモーターの単核性多形態 (SNPs) を特定する.
- これらのSNPがPASMCにおけるTRPC6活性を調節する際の機能的重要性を決定する.
主な方法:
- ゲノムDNAは,正常な被験者とIPAH患者の血液サンプルから分離した.
- TRPC6プロモーターに3つのバイアレルSNP (-361, -254, -218) が同定されました.
- 機能分析では,核因子-カッパB (NF-κB) 結合とTRPC6発現に対するSNPの影響を評価した.
主要な成果:
- -254 ((C-->G) SNPアレル頻度は,正常な被験者 (6%) よりも,IPAH患者 (12%) で有意に高かった.
- -254(C-->G) SNPはNF-κB結合部位を作り,NF-κB媒介のTRPC6プロモーター活性とTRPC6発現を高めます.
- NF-κBの阻害は,−254Gアレルを持つIPAH患者におけるTRPC6発現とCa2+流入を減少させた.
結論:
- TRPC6プロモーターの -254(C-->G) SNPは,IPAHのリスクを増加させる可能性があります.
- このSNPは,異常なTRPC6転写を,炎症性転写因子であるNF-κBと結びつける.
- NF-κBをターゲットにすることは,IPAHの治療の可能性を提示する可能性があります.
関連する概念動画
Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


